MaaT Pharma (MAAT.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $106.8M

Market Cap: $145.4MFounded: 2014HQ: Lyon, France

Sector Ranking#3 in Microbiome Therapeutics #116 in Oncology (General)

Overview

MaaT Pharma is a clinical-stage company focused on leveraging the gut microbiome to improve survival in cancer patients. Its core strategy is built on a differentiated 'full ecosystem' therapeutic platform, with lead candidate MaaT013 in Phase 3 for acute Graft-versus-Host Disease (aGvHD). The company has established integrated R&D and cGMP manufacturing capabilities and is publicly traded on Euronext Paris to fund its ambitious late-stage clinical programs.

OncologyHematology

Technology Platform

Microbiome Ecosystem Therapy (MET) platform designed to capture, preserve, and restore the full diversity of a healthy human gut microbiome, supported by AI-driven drug development and integrated cGMP manufacturing.

Funding History

4

Total raised:$106.8M

IPO$50MEuronext ParisSep 23, 2021

Series B$34MSymBiosisJul 15, 2020

Series A$20MSeventure PartnersMar 15, 2018

Seed$2.8MSeventure PartnersSep 15, 2014

Opportunities

Positive Phase 3 data for MaaT013 in aGvHD could lead to first-in-class approval and establish the full-ecosome platform.

The oral capsule MaaT033 opens a larger preventive market in hemato-oncology supportive care, and the platform has long-term potential in combination with immuno-oncology agents for solid tumors.

Risk Factors

High clinical risk with pivotal Phase 3 data pending.

Complex manufacturing and unique regulatory pathway for a full-ecosystem live biotherapeutic.

Pre-revenue status necessitates future capital raises, posing dilution risk.

Competitive Landscape

Competes with defined-consortium microbiome firms (Seres, Vedanta) and small molecule drugs in aGvHD. Key differentiation is the 'full ecosystem' approach, aiming to restore complete microbial diversity for durable immune modulation, a novel mechanism versus immunosuppressants.